地图样萎缩中的视力丧失:来自兰帕珠单抗试验的启示
该研究回顾性分析兰帕珠单抗3期试验及前瞻性观察试验中双侧地图样萎缩(GA)患者,评估基线BCVA、GA面积及病灶生长速率与视力丧失的关系。基线BCVA和GA面积与BCVA变化不相关,但较快的GA生长速率似乎与较快的BCVA丧失相关;中心凹下受累且单灶性病灶视力丧失风险较高。
要点
- 基线BCVA和GA面积与随访中BCVA变化不相关。
- GA生长速率与BCVA丧失呈弱相关,且随时间增强。
- 中心凹下、单灶性病灶在GA生长速率最高的两个四分位组中BCVA丧失加速。
核心结论
- 基线BCVA和GA面积与BCVA丧失不相关,但较快的GA生长速率似乎与较快的BCVA丧失相关。
- GA中心凹受累和灶性分布与BCVA丧失速率相关,中心凹下病灶随时间视力丧失风险高,尤其是GA病灶为单灶性时。
研究设计与样本
- 回顾性分析兰帕珠单抗3期试验(NCT02247479和NCT02247531)及前瞻性观察试验(NCT02479386)。
- 研究对象为双侧地图样萎缩(GA)患者。
- 每月测量BCVA,基线和每6个月进行眼底自发荧光(FAF)检查,持续2年。
主要发现
- 基线BCVA和GA面积与任何访视时的BCVA变化均不相关。
- GA生长速率与BCVA丧失呈弱相关,且随时间推移相关性增强。
- GA生长速率最高的两个四分位组中,中心凹下、单灶性病灶眼的BCVA丧失加速。
- 约75%的研究眼在2年内发生≥5个字母的丧失,约50%发生≥10个字母的丧失,约25%发生≥15个字母的丧失。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the correlation of lesion growth rate and baseline factors, including foveal involvement and focality, on visual loss as measured by best-corrected visual acuity (BCVA) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). DESIGN: Retrospective analysis of the lampalizumab phase 3 (NCT02247479 and NCT02247531) and prospective observational (NCT02479386) trials. PARTICIPANTS: Patients with bilateral GA. METHODS: Monthly BCVA and fundus autofluorescence (FAF) at baseline and every 6 months for 2 years were analyzed. Baseline GA area from FAF images was correlated to baseline BCVA and change in BCVA. The lesion growth rate was calculated as the slope of a linear fit from all available GA area measurements of a patient. The association between GA growth rate quartiles and BCVA changes was assessed, subgrouped by GA foveal involvement or focality. Time-to-event analysis for BCVA loss of ≥5, ≥10, and ≥15 letters was performed. A Cox regression model adjusted for baseline factors was performed on these outcomes. Kaplan-Meier curves are provided for each baseline factor and GA growth rate. MAIN OUTCOME MEASURES: Correlations of baseline BCVA, GA area, and growth rate with change in BCVA, and time to ≥5, ≥10, and ≥15-letter loss by foveal involvement or focality. RESULTS: Best-corrected visual acuity and GA area at baseline did not correlate with BCVA change at any visit. Geographic atrophy growth rate showed a weak correlation with BCVA loss, which increased over time. The 2 highest GA growth rate quartiles had accelerated BCVA loss in eyes with subfoveal, unifocal lesions. Approximately 75%, 50%, and 25% of study eyes experienced a ≥5-, ≥10-, and ≥15-letter loss by 2 years, respectively. CONCLUSIONS: Best-corrected visual acuity and GA area at baseline did not correlate with BCVA loss, but faster GA growth rates appeared to be associated with faster BCVA loss. Geographic atrophy foveal involvement and focality correlated with the rate of BCVA loss with subfoveal lesions at high risk of vision loss over time, especially when the GA lesion was unifocal. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
引用
- Anegondi N, Steffen V, Sadda SR, et al. Visual Loss in Geographic Atrophy: Learnings from the Lampalizumab Trials. Ophthalmology. 2024. PMID: 39581330. doi:10.1016/j.ophtha.2024.11.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。